Abstract

Join us for an evening on how AI is redefining what’s possible in synthetic biology, spanning next-generation medicines, sustainable manufacturing, and the global food industry.

Synthetic biology holds the promise of sustainable chemicals, advanced biomolecules, and resilient crops. Yet biology’s complexity makes the journey from lab to market long, costly, and unpredictable.

AI is changing that. From protein design and enzyme engineering to strain optimization and bioprocess scale-up, AI tools are unlocking capabilities once out of reach.

This panel brings together perspectives from a protein-design startup for pharma and life sciences, a biotech creating novel materials, and a deep-tech venture capital investor. We’ll explore how AI is enabling the next wave of medicines, materials and, and food –  and what investors look for in AI-driven synbio biology ventures.

Panelists

Dr. Ingmar Schuster is the Co-founder and CEO of Provolut, a German biotech startup. Provolut focuses on designing and optimizing proteins using AI for biotech, pharma and chemistry clients.

Pierre Salvy, PhD, is the CTO at Cambrium. The company uses generative AI and biotechnology to design, develop, and scale new molecules to power the chemistry of tomorrow.

Dr. Carolina Villa is Principal at Nucleus Capital, a deep-tech VC focused on Programmable Biology, Food Technology and Green Industrials.

Everyone is welcome, space is limited. Registration via Luma is required.

Subscribe to our newsletter for priority invitations to upcoming events or follow us on Luma.